Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
复制标题
DOI：
10.1038/leu.2011.196
复制
发表时间：
2012-01
期刊：
影响因子：
11.4
通讯作者：
International Myeloma Working Group
中科院分区：
文献类型：
--
作者：
Kumar SK;Lee JH;Lahuerta JJ;Morgan G;Richardson PG;Crowley J;Haessler J;Feather J;Hoering A;Moreau P;LeLeu X;Hulin C;Klein SK;Sonneveld P;Siegel D;Bladé J;Goldschmidt H;Jagannath S;Miguel JS;Orlowski R;Palumbo A;Sezer O;Rajkumar SV;Durie BG;International Myeloma Working Group
目前正在评估有前景的新药用于治疗多发性骨髓瘤 (MM)，但其影响应根据当前治疗失败的患者的预期结果来衡量。然而，当今时代复发性疾病的自然史仍不清楚。我们研究了 286 名复发性 MM 患者，他们对硼替佐米耐药，并且复发、难治或不适合 IMiD（免疫调节药物），可测量疾病和 ECOG PS 为 0、1 或 2。患者满足进入标准的日期定义为零时间 (T0)。诊断时的中位年龄为 58 岁，从诊断到 T0 的时间为 3.3 年。 T0 之后，213 名 (74%) 患者接受了一种或多种治疗方案记录的治疗（中位数 = 1；范围 0-8）。第一个方案中，55 名 (26%) 患者使用硼替佐米，70 名 (33%) 患者使用 IMiD。 94 名患者 (51%) 在 T0 后至少对一种治疗有轻微反应或更好，其中 69 名患者 (38%) ≥部分反应。 T0 起的中位总生存期和无事件生存期分别为 9 个月和 5 个月。这项研究证实，一旦患者对当前的治疗产生耐药性，结果就会很差。结果为解释正在进行的新药试验提供了背景。
Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were refractory to bortezomib and were relapsed, refractory, or ineligible, to an IMiD (Immunomodulatory Drug), with measurable disease and ECOG PS of 0, 1 or 2. The date patients satisfied the entry criteria was defined as time zero (T0). The median age at diagnosis was 58 years and time from diagnosis to T0 was 3.3 years. Following T0, 213 (74%) patients had a treatment recorded with one or more regimens (median=1; range 0-8). The first regimen contained bortezomib in 55 (26%) patients and an IMiD in 70 (33%). A minor response or better was seen to at least one therapy after T0 in 94 patients (51%) including >=partial response in 69 (38%). The median overall survival and event free survival from T0 were 9 and 5 months respectively. This study confirms the poor outcome once patients become refractory to current treatments. The results provide context for interpreting ongoing trials of new drugs.
登录
查看更多内容
Vorinostat与Bortezomib结合的I阶段研究，用于复发和难治性多发性骨髓瘤。
影响因子：
11.5
作者：
Badros, Ashraf;Burger, Angelika M.;Philip, Sunita;Niesvizky, Ruben;Kolla, Sarah S.;Goloubeva, Olga;Harris, Carolynn;Zwiebel, James;Wright, John J.;Espinoza-Delgado, Igor;Baer, Maria R.;Holleran, Julianne L.;Egorin, Merrill J.;Grant, Steven
通讯作者：
Grant, Steven
影响因子：
11.4
作者：
通讯作者：
--
影响因子：
20.3
作者：
Avet-Loiseau, Herve;Attal, Michel;Mathiot, Claire
通讯作者：
Mathiot, Claire
影响因子：
11.4
作者：
Durie, B. G. M.;Harousseau, J-L;Rajkumar, S. V.
通讯作者：
Rajkumar, S. V.
影响因子：
20.3
作者：
Rajkumar, SV;Hayman, SR;Gertz, MA
通讯作者：
Gertz, MA